Beta Bionics (NASDAQ:BBNX) Issues Earnings Results

Beta Bionics (NASDAQ:BBNX) announced its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12, FiscalAI reports. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%.

Here are the key takeaways from Beta Bionics’ conference call:

• Beta Bionics reported strong commercial momentum in 2025 with $100.3M in net sales (up 54% YoY), >35,000 cumulative iLet users, ~20,000 new users in 2025, and Q4 revenue of $32.1M driven by 5,592 new patient starts and rising pharmacy adoption.
• The company guided 2026 revenue to $130M–$135M with gross margin of 55.5%–57.5% and at least 20 new sales territories, while warning OpEx and CapEx will increase (notably for sales expansion, Mint and bihormonal R&D), which makes near-term profitability and revenue cadence more conservative versus 2025.
• Beta Bionics received an FDA Warning Letter related to quality-system issues (complaint handling/MDR definitions, CAPA, tracking/trending, and corrections/removals); management says remediation is underway and expects resolution by end of Q2 but the letter represents regulatory risk.
• R&D progress continues: the Mint patch pump is tracking to an unconstrained commercial launch by end of 2027 and management expects strong long-term gross margins, while the bihormonal system completed a first-in-human feasibility trial and will advance additional phase 2A work toward later pivotal studies.

Beta Bionics Trading Up 0.2%

Shares of NASDAQ:BBNX opened at $13.97 on Wednesday. The firm’s 50 day moving average is $22.10 and its two-hundred day moving average is $22.60. The firm has a market capitalization of $615.10 million and a P/E ratio of -3.20. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $32.71.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BBNX shares. Bank of America downgraded Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. Truist Financial decreased their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. UBS Group upgraded Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Finally, Piper Sandler reiterated an “overweight” rating and set a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and a consensus price target of $25.00.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beat on revenue and EPS context: Q4 net sales rose 57% YoY to $32.1M and the company reported GAAP EPS of ($0.30) which beat the consensus loss. Management highlighted sizable growth in both DME and pharmacy channels, supporting near-term topline momentum. Press Release
• Positive Sentiment: Raised 2026 revenue outlook: Beta Bionics guided to ~$130M–$135M for 2026 (above consensus cited in reports), and expects higher PBP reimbursement mix and stable gross margins — a material driver of today’s positive sentiment. Guidance/Strategy Note
• Positive Sentiment: Commercial traction: Installed base jumped to ~35k users (up 129% YoY) and PBP (pharmacy benefit plan) channel sales surged ~295% YoY — evidence the multi-channel reimbursement strategy is scaling. Quiver/Release Summary
• Neutral Sentiment: Clinical progress: The company completed a first-in-human Phase 2a feasibility trial for its bihormonal system and plans an additional Phase 2a in H1/2026 — important for long-term value but not immediate revenue. Clinical Update
• Neutral Sentiment: Earnings detail and call/transcript: Management hosted a call detailing channel mix, patient starts, and margin targets — useful for modeling but largely confirming the written guidance. Earnings Call Transcript
• Negative Sentiment: Profitability and cash burn remain concerns: Q4 and FY25 GAAP losses and negative adjusted EBITDA persist (adjusted EBITDA still negative), meaning the company must demonstrate sustained margin improvement to justify higher multiples. Financials/10-K Style Release
• Negative Sentiment: Investor litigation notices: Two law firms announced investigations into Beta Bionics, which can create headline volatility and legal overhang. Faruqi & Faruqi Investigation Pomerantz Alert
• Negative Sentiment: Analyst stance and insider activity: TD Cowen kept a Hold with a $16 PT (below many bullish targets) and recent disclosures show notable insider sales reported in #sourced summaries — both can temper upside. Analyst Note

Insider Buying and Selling

In related news, CFO Stephen Feider sold 20,000 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Mike Mensinger sold 7,800 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.61, for a total value of $230,958.00. Following the transaction, the insider owned 82,952 shares of the company’s stock, valued at $2,456,208.72. This trade represents a 8.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 32,490 shares of company stock valued at $960,835 over the last three months.

Institutional Investors Weigh In On Beta Bionics

Institutional investors have recently bought and sold shares of the stock. GPS Wealth Strategies Group LLC increased its stake in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after buying an additional 450 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Beta Bionics by 203.6% in the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares in the last quarter. Strs Ohio acquired a new position in shares of Beta Bionics during the first quarter valued at approximately $29,000. Ameritas Investment Partners Inc. raised its holdings in Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock worth $64,000 after purchasing an additional 1,863 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after purchasing an additional 2,639 shares during the period.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.